Resource Center: Research report

This clinical guideline describes the off-label use of buprenorphine and buprenorphine/naloxone to treat pain syndromes.

This is a brief list of risk and protective factors to look for when evaluating patients for substance abuse.

This chapter from TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs discusses the use of drug testing as a means of monitoring patient progress and treatment efficacy. This chapter details several methods for implementing drug testing, their effectiveness, and their pros and cons.

This is a brief list of risk factors to look for when evaluating patients for substance abuse. There is also guidance on how health professionals can mitigate adolescent risk for substance abuse.

This guide contains information for health care providers on the problem of drug-exposed infants and their families. Topics covered include medical management, followup and aftercare, psychosocial services, ethical and legal guidelines, and quality assurance.

This report describes points of intersection between HIV and primary care treatment, and discusses how to integrate HIV care into primary medicine.

This publication discusses the medical co-management of hepatitis infection and opioid abuse.

This presentation discusses diversion of Subutex® and Suboxone® both in a general sense and in the specific case of the RADARS system, a nonprofit governmental program through the Rocky Mountain Poison and Drug Center.

This report, written in 2006, evaluates patient outcomes and patient and physician attitudes since the passage of DATA 2000, and examines challenges facing buprenorphine treatment going forward.

This research report from NIDA discusses the scope of heroin use in the US, immediate and long term effects of heroin use, the medical complications of heroin use, how heroin abuse affects pregnant women, and more. It also discusses treatments for heroin addiction, including buprenorphine.